Advertisement

Heart Failure in South Asian Population

  • Pallavi SolankiEmail author

Abstract

Heart Failure (HF) is one of the major cardiovascular syndromes that is increasing in prevalence throughout the world and is associated with significant morbidity and mortality. There is overwhelming evidence that heart failure is an epidemic in South Asians with higher rates of hospitalizations and increased morbidity compared to other ethnic groups, particularly White. Current data demonstrate that South Asians with heart failure are predominantly younger than patients of other ethnic background. Advances in understanding of heart failure over the past two decades have led to important advances in therapy. Despite these advances, there is limited information available on the exact prevalence, incidence, evidence-based management, and mortality associated with heart failure in South Asians. This clearly underscores the need for further research in this particularly vulnerable population to better understand this syndrome of heart failure and to help formulate guidelines for appropriate management of heart failure in South Asians. This chapter outlines the key points of heart failure syndrome in South Asians including risk factors, diagnosis and management options in this population.

Keywords

Heart Failure South Asians Coronary artery disease Hypertension Risk factors Imaging 

References

  1. 1.
    Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2014 Jan 21;129(3):399–410.Google Scholar
  2. 2.
    Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Shantsila E, Lip GY, Gill PS. Systolic heart failure in South Asians. Int J Clin Pract. 2011;65:1274–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics–2011 update: a report from the American heart association. Circulation. 2011;123:e18–209.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. BMJ. 2004;328:807–10.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Libby P, Braunwald E. Braunwald’s heart disease: a textbook of cardiovascular medicine. Philadelphia: Saunders/Elsevier; 2008.Google Scholar
  8. 8.
    Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–18.CrossRefPubMedGoogle Scholar
  9. 9.
    Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47:320–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol. 2001;38:1277–82.CrossRefPubMedGoogle Scholar
  12. 12.
    2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147–239.Google Scholar
  13. 13.
    Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J. 1996;48:343–53.PubMedGoogle Scholar
  14. 14.
    Pais P, Pogue J, Gerstein H, Zachariah E, Savitha D, Jayprakash S, Nayak PR, Yusuf S. Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet. 1996;348:358–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Chadha SL, Radhakrishnan S, Ramachandran K, Kaul U, Gopinath N. Epidemiological study of coronary heart disease in urban population of Delhi. Indian J Med Res. 1990;92:424–30.PubMedGoogle Scholar
  16. 16.
    Reddy KS. Cardiovascular diseases in India. World Health Stat Q. 1993;46:101–7.PubMedGoogle Scholar
  17. 17.
    Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular and cancer mortality among Canadians of European, South Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ. 1999;161:132–8.PubMedCentralPubMedGoogle Scholar
  18. 18.
    McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in South Asians overseas: a review. J Clin Epidemiol. 1989;42:597–609.CrossRefPubMedGoogle Scholar
  19. 19.
    Balarajan R. Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. BMJ. 1991;302:560–4.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Singh N, Gupta M. Clinical characteristics of South Asian patients hospitalized with heart failure. Ethn Dis. 2005;15:615–9.PubMedGoogle Scholar
  21. 21.
    Gupta M, Doobay AV, Singh N, Anand SS, Raja F, Mawji F, Kho J, Karavetian A, Yi Q, Yusuf S. Risk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects. CMAJ. 2002;166:717–22.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet. 2005;366:1744–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Murray CJL, Lopez AD, Harvard School of Public Health, World Health Organization, World Bank. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank; Distributed by Harvard University Press; 1996.Google Scholar
  24. 24.
    Gupta M, Brister S. Is South Asian ethnicity an independent cardiovascular risk factor? Can J Cardiol. 2006;22:193–7.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Mohan V, Deepa R, Rani SS, Premalatha G. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: the Chennai urban population study (cups no. 5). J Am Coll Cardiol. 2001;38:682–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Enas EA, Mehta J. Malignant coronary artery disease in young Asian Indians: thoughts on pathogenesis, prevention, and therapy. Coronary Artery Disease in Asian Indians (CADI) Study. Clin Cardiol. 1995;18:131–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, Lonn E, Gerstein H, Hegele RA, McQueen M. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The study of health assessment and risk in ethnic groups (share). Lancet. 2000;356:279–84.CrossRefPubMedGoogle Scholar
  28. 28.
    McKeigue PM, Marmot MG. Mortality from coronary heart disease in Asian communities in London. BMJ. 1988;297:903.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Dhawan J, Bray CL. Angiographic comparison of coronary artery disease between Asians and Caucasians. Postgrad Med J. 1994;70:625–30.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension. 2007;50:991–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Hughes LO, Cruickshank JK, Wright J, Raftery EB. Disturbances of insulin in British Asian and white men surviving myocardial infarction. BMJ. 1989;299:537–41.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991;337:382–6.CrossRefPubMedGoogle Scholar
  33. 33.
    McKeigue PM, Ferrie JE, Pierpoint T, Marmot MG. Association of early-onset coronary heart disease in South Asian men with glucose intolerance and hyperinsulinemia. Circulation. 1993;87:152–61.CrossRefPubMedGoogle Scholar
  34. 34.
    Dhandapany PS, Sadayappan S, Xue Y, Powell GT, Rani DS, Nallari P, Rai TS, Khullar M, Soares P, Bahl A, Tharkan JM, Vaideeswar P, Rathinavel A, Narasimhan C, Ayapati DR, Ayub Q, Mehdi SQ, Oppenheimer S, Richards MB, Price AL, Patterson N, Reich D, Singh L, Tyler-Smith C, Thangaraj K. A common MYBPC3 (cardiac myosin binding protein c) variant associated with cardiomyopathies in South Asia. Nat Genet. 2009;41:187–91.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? JAMA. 1997;277:1712–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med. 2002;112:437–45.CrossRefPubMedGoogle Scholar
  37. 37.
    Ghali JK, Kadakia S, Cooper RS, Liao YL. Bedside diagnosis of preserved versus impaired left ventricular systolic function in heart failure. Am J Cardiol. 1991;67:1002–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. QRS duration and mortality in patients with congestive heart failure. Am Heart J. 2002;143:1085–91.CrossRefPubMedGoogle Scholar
  39. 39.
    Mahdyoon H, Klein R, Eyler W, Lakier JB, Chakko SC, Gheorghiade M. Radiographic pulmonary congestion in end-stage congestive heart failure. Am J Cardiol. 1989;63:625–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Vinch CS, Aurigemma GP, Hill JC, Gaasch WH, Volturo G, Tighe DA, Meyer TE. Usefulness of clinical variables, echocardiography, and levels of brain natriuretic peptide and norepinephrine to distinguish systolic and diastolic causes of acute heart failure. Am J Cardiol. 2003;91:1140–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.CrossRefPubMedGoogle Scholar
  42. 42.
    Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta stone. J Am Coll Cardiol. 1997;30:8–18.CrossRefPubMedGoogle Scholar
  43. 43.
    Garcia MJ, Rodriguez L, Ares M, Griffin BP, Thomas JD, Klein AL. Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging. J Am Coll Cardiol. 1996;27:108–14.CrossRefPubMedGoogle Scholar
  44. 44.
    McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation. 2002;106:416–22.CrossRefPubMedGoogle Scholar
  45. 45.
    Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–82.CrossRefPubMedGoogle Scholar
  46. 46.
    Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS. Utility of b-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379–85.CrossRefPubMedGoogle Scholar
  47. 47.
    Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN. Direct comparison of b-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528–38.CrossRefPubMedGoogle Scholar
  48. 48.
    Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E. Prognostic value of b-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol. 2007;50:205–14.CrossRefPubMedGoogle Scholar
  49. 49.
    Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914–31.CrossRefPubMedGoogle Scholar
  50. 50.
    Colin Ramirez E, Castillo Martinez L, Orea Tejeda A, Rebollar Gonzalez V, Narvaez David R, Asensio Lafuente E. Effects of a nutritional intervention on body composition, clinical status, and quality of life in patients with heart failure. Nutrition. 2004;20:​890–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.Google Scholar
  52. 52.
    Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.CrossRefPubMedGoogle Scholar
  53. 53.
    A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). CIBIS investigators and committees. Circulation. 1994;90:1765–73Google Scholar
  54. 54.
    The cardiac insufficiency bisoprolol study ii (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.Google Scholar
  55. 55.
    Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (comet): randomised controlled trial. Lancet. 2003;362:7–13.CrossRefPubMedGoogle Scholar
  56. 56.
    Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial study group. N Engl J Med. 1987;316:1429–35.Google Scholar
  57. 57.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10.CrossRefPubMedGoogle Scholar
  58. 58.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293–302.Google Scholar
  59. 59.
    Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–8.Google Scholar
  60. 60.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown Jr EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The save investigators. N Engl J Med. 1992;327:669–77.CrossRefPubMedGoogle Scholar
  61. 61.
    Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (trace) study group. N Engl J Med. 1995;333:1670–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan heart failure mortality meta-analysis study group. Am J Cardiol. 2000;85:187–92.CrossRefPubMedGoogle Scholar
  63. 63.
    Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the charm-alternative trial. Lancet. 2003;362:772–6.CrossRefPubMedGoogle Scholar
  64. 64.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the charm-added trial. Lancet. 2003;362:767–71.CrossRefPubMedGoogle Scholar
  65. 65.
    Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.CrossRefPubMedGoogle Scholar
  66. 66.
    Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The Ephesus trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-ami heart failure efficacy and survival study. Cardiovasc Drugs Ther. 2001;15:79–87.CrossRefPubMedGoogle Scholar
  67. 67.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.CrossRefPubMedGoogle Scholar
  68. 68.
    Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387–95.CrossRefPubMedGoogle Scholar
  69. 69.
    Heart Failure Society Of A. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–2.CrossRefGoogle Scholar
  70. 70.
    The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525–33.Google Scholar
  71. 71.
    Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. Radiance study. N Engl J Med. 1993;329:1–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Pieper K, Sun JL, Yancy C, Young JB. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61–70.CrossRefPubMedGoogle Scholar
  73. 73.
    Zannad F, Mebazaa A, Juilliere Y, Cohen-Solal A, Guize L, Alla F, Rouge P, Blin P, Barlet MH, Paolozzi L, Vincent C, Desnos M, Samii K. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail. 2006;8:697–705.CrossRefPubMedGoogle Scholar
  74. 74.
    Cuffe MS, Califf RM, Adams Jr KF, Benza R, Bourge R, Colucci WS, Massie BM, O’Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–7.CrossRefPubMedGoogle Scholar
  75. 75.
    Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (adhere). J Am Coll Cardiol. 2005;46:57–64.CrossRefPubMedGoogle Scholar
  76. 76.
    Allen LA, O’Connor CM. Management of acute decompensated heart failure. CMAJ. 2007;176:797–805.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams Jr KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.CrossRefPubMedGoogle Scholar
  78. 78.
    Jaski BE, Ha J, Denys BG, Lamba S, Trupp RJ, Abraham WT. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail. 2003;9:227–31.CrossRefPubMedGoogle Scholar
  79. 79.
    Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, Mackedanz S, Sobotka PA, Schollmeyer M, Goldsmith SR. Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid-overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043–6.CrossRefPubMedGoogle Scholar
  80. 80.
    Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.CrossRefPubMedGoogle Scholar
  81. 81.
    Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the escape trial. JAMA. 2005;294:1625–33.CrossRefPubMedGoogle Scholar
  82. 82.
    Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM, Sopko G, Califf RM. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA. 2005;294:1664–70.CrossRefPubMedGoogle Scholar
  83. 83.
    Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.CrossRefPubMedGoogle Scholar
  84. 84.
    Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.CrossRefPubMedGoogle Scholar
  85. 85.
    Strickberger SA, Conti J, Daoud EG, Havranek E, Mehra MR, Pina IL, Young J. Patient selection for cardiac resynchronization therapy: from the council on clinical cardiology subcommittee on electrocardiography and arrhythmias and the quality of care and outcomes research interdisciplinary working group, in collaboration with the heart rhythm society. Circulation. 2005;111:2146–50.CrossRefPubMedGoogle Scholar
  86. 86.
    Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefPubMedGoogle Scholar
  87. 87.
    Freemantle N, Tharmanathan P, Calvert MJ, Abraham WT, Ghosh J, Cleland JG. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction – a systematic review and meta-analysis. Eur J Heart Fail. 2006;8:433–40.CrossRefPubMedGoogle Scholar
  88. 88.
    Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, Starling RC, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1–39.CrossRefPubMedGoogle Scholar
  89. 89.
    Stone ME. Current status of mechanical circulatory assistance. Semin Cardiothorac Vasc Anesth. 2007;11:185–204.CrossRefPubMedGoogle Scholar
  90. 90.
    Deng MC, Smits JM, Young JB. Proposition: the benefit of cardiac transplantation in stable outpatients with heart failure should be tested in a randomized trial. J Heart Lung Transplant. 2003;22:113–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Internal MedicineThe Ohio State University Medical CenterColumbusUSA

Personalised recommendations